Despite Negative New York Times Article "Dubius Cardiac", Jefferies Maintains Buy on HCA Inc (HCA)

A DOJ inquiry and newly released New York Times article discussing "dubious cardiac" clinical and billing practices at HCA Inc (NYSE: HCA) has added a new overhang to this stock, thinks Arthur Henderson, an analyst at Jefferies.

"However, as prospects for another special dividend grow, these anxieties will abate, and the stock will likely move higher," said Henderson.

Jefferies has a Buy rating on HCA Holdings (NYSE: HCA). They firm lowered the price target to $30.00 (from $34.00) to reflect overhangs.

For an analyst ratings summary and ratings history on HCA Holdings click here. For more ratings news on HCA Holdings click here.

Shares of HCA Holdings closed at $25.55 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Clear Street Reiterates Buy Rating on Anterix Inc. (ATEX)
• Benchmark Reiterates Buy Rating on NVIDIA (NVDA), Updates Estimates